The aim of the present study was to investigate hidden distress originating from the expected pharmacological features in clinical practice using questionnaires, one of the best methods to communicate distress without the difficulties of verbal communication.
Introduction
Symptoms in patients with schizophrenia are usually treated with antipsychotics, including first-generation antipsychotics (FGAs; e. g. chlorpromazine and haloperidol), second-generation antipsychotics (SGAs; e. g. risperidone, quetiapine and olanzapine) and non-sedative SGAs (aripiprazole, blonanserin and amisulpride) 1) . FGAs usually block strong dopamine (DA) D2 receptors and affect positive symptoms such as conceptual disorganisation, suspiciousness, hallucinatory behaviour and unusual thought content. However, FGAs cause side effects such as extra-pyramidal symptoms (EPS), hyper-prolactinemia (due to D2 receptor block), excessive sedation and weight gain (due to histaminic H1 receptor block) 2) 3) . SGAs affect both positive and negative symptoms, such as blunted affect, which are difficult to treat with FGAs. In addition, EPS side effects are also lower with SGAs than with FGAs. These two main features of SGAs appear to have greater advantages than those of FGA, but these types of drugs produce another noteworthy side effect, metabolic syndrome 4) . Non-sedative SGAs, such as aripiprazole (partial agonist not only for D2 and D3 receptors), blonanserin and amisulpride (they block not only D2 receptors but also D3 receptors), are expected to improve residual symptoms without severe side effects (almost no M1, α1 or H1 receptor blockade). Thus, for prescribing pharmacological therapy to patients with schizophrenia, psychiatrists should carefully consider the benefit and risk of medications for each patient. However, these pharmacological features of antipsychotics administered, which are based on pharmacological features in vitro, may not translate to practical clinical pharmacology because the main effects and side effects may be due to individual differences among patients, including genetic features 5) .
Patients with schizophrenia often have difficulty explaining their distress by verbal communication because of symptoms such as thought disorder and/or motor retardation. In addition, verbal communication is sometimes difficult regarding sexual side effects, such as erectile disorder, gynecomastia and menstruation disorders, especially when talking to a doctor of the opposite sex 6) . The use of questionnaires is one of the best methods for allowing patients to report their distress without involving difficult verbal communication 7) . Rather than reporting the distress in qualitative interviews, self-administered questionnaires are preferred for revealing hidden distress 8) . Questionnaires have been used to investigate side effects when considering the quality of life of patients during the basis of practical clinical pharmacotherapy, which does not control for the type and/or dose of antipsychotics used. Because pharmacotherapy using antipsychotics in clinical psychiatry has a history of severe side effects, questionnaire studies have often considered the risk of side effects, but not beneficial effects. To assess the quality of life in patients with schizophrenia, the balance between risk and benefit should be simultaneously investigated with questionnaires 9) .
In the present study, we conducted a study using questionnaires given to medicated outpatients with schizophrenia to investigate whether their satisfaction or dissatisfaction with antipsychotics was different according to the type of antipsychotic used as predicted by pharmacological theory.
Material and methods

Participants
Fifty-seven Japanese patients with chronic schizophrenia (25 males and 32 females; age, 44.8±13.5 years; range, 19-69 years; duration of illness, 10.2±5.2 years; range, 4-27 years; medicated duration, 9.2±5.0 years; range, 3-25 years) that met the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of schizophrenia and who were outpatients of the Juntendo University Hospital (Table-1 ) were included in this study. At the time of examination, 21 patients were taking only FGAs (e.g. haloperidol, chlorpromazine), 20 were taking only sedative SGAs (S-SGA; olanzapine, risperidone or quetiapine), 5 were taking only non-sedative-SGAs (NS-SGA; aripiprazole or blonanserin) and 11 were taking both types of antipsychotics (FGAs and S-SGA or NS-SGA). The daily doses of the antipsychotic and concomitant anticholinergic medications were converted into antipsychotics equivalent dose (chlorpromazine equivalent dose; CP dose) 10) 11) and anticholinergic agent equivalent dose (AC dose) 12) , respectively. The clinical symptoms of the patients with schizophrenia were evaluated using the Clinical Global Impressions-Severity scale (CGI-S). The Ethics Committee of the Juntendo University Faculuty of Medicine approved this study (23-299). All patients gave written informed consent to participate.
Questionnaire for satisfaction and side effects
A poster with information about the questionnaire for satisfaction and side effects was placed on the wall of the waiting room of the psychiatry unit for outpatients. The questionnaire could be picked up by the patients, and completed questionnaires were handed to their doctor or nurse.
The questionnaire comprised 14 items for satisfaction from the Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM) 13) ( A3. How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?
A4. For your current any side effects at all, please answer mentioned below 5-8, and also (B) Side Effect Questionnaire a .
A5. How bothersome are the side effects of the medication you take to treat your condition? (1) (2) (3) (4) (5) A6. To what extent do the side effects interfere with your physical health and ability to function (i.e., strength, energy levels, etc.)? (1) (2) (3) (4) (5) A7. To what extent do the side effects interfere with your mental function (i.e., ability to think clearly, stay awake, etc.)? (1) (2) (3) (4) (5) A8. To what degree have medication side effects affected your overall satisfaction with the medication?
. How easy or difficult is it to use the medication in its current form?
A10. How easy or difficult is it to plan when you will use the medication each time?
A11. How convenient or inconvenient is it to take the medication as instructed?
A12. Overall, how confident are you that taking this medication is a good thing for you? (1) (2) (3) (4) (5) A13. How certain are you that the good things about your medication outweigh the bad things? (1) (2) (3) (4) (5) A14. Taking all things into account, how satisfied or dissatisfied are you with this medication?
(1-7)
Subscales
Effectiveness (A1+ A2+ A3) (3-21)
Side effect (A5+ A6+ A7+ A8) (4-20)
Convenience (A9+ A10+ A11) (3-21)
Global satisfaction (A12+ A13+ A14) ( EPS; Extra pyramidal symptoms. For the items, A1-A3 and A9-A11, these items are scaled on a seven point (five point for A12 and 13) bipolar scale from 'Extremely Satisfied (1)' to 'Extremely Dissatisfied (7) '. For the side effects items A5-A8, these items are scaled on a five point bipolar scale from 'Extremely Distressed (1)' to 'No Distress at all (5)'. a This questionnaire item in TSQM were modified to investigate the anti-psychotics induced side effects in detail with (B) Side Effect Questionnaire. Original item in TSQM is " As a result of taking this medication, do you currently experience any side effects at all? (yes or no)". b Because number of sexual side effects each item for male (5 subscales; 8, 9, 11, 12 and 13, and sum of full marks for these were 20) were more than that of female (3 subscales; 8, 9 and 10, and sum of full marks for these were 12), thus the total score for sexual subscale categories for female were multiplied by 20/12 to correct the difference between gender. Because the number of sexual side effects items for males (5 subscales; 8, 9, 11, 12 and 13; sum of full marks for these was 20) was more than that for females (3 subscales; 8, 9 and 10; sum of full marks for these was 12), the total score for sexual subscale categories for females was multiplied by 20/12 to correct the difference between genders.
Statistical Analysis
To verify the parallelism for regression, betweensubjects interaction analysis was performed by investigating the interaction between the type of antipsychotic used (fixed factor) and the CP dose (assumed covariate). Three dependent variables, effectiveness (p=0.016), convenience (p=0.031) and sedation (p=0.027), showed significant interactions between the type of antipsychotic used and the CP dose. No dependent variables showed significant regression with the assumed covariate (CP dose) (Table-3) , and thus, analysis of covariance was not applied. In addition, the number of some subgroups was small, and dependent variables from these subgroups were far from normal distribution. Thus, the differences in subscale scores from questionnaires between the groups classified by the type of antipsychotic used (e. g. FGAs or S-SGAs) were compared using non-parametric analysis with the Kruskal-Wallis test. If there were any significance among the groups, the two-tailed Mann-Whitney U test were used for the post-hoc test with the corrected p-value by Bonferroni correction for the means of multiple comparisons (p< 0.05 was divided by the number of comparisons). The relationships among the questionnaire scores and clinical variables shown in Table 3 were evaluated using the twotailed Spearmanʼs rank correlation.
Results
Differences in clinical variables and subscale scores in questionnaires between groups classified according to the type of antipsychotic used
The clinical variables and subscales from questionnaires were compared among the groups classified by the type of antipsychotic used (Table-1 ). As expected, the mean age of patients medicated with FGAs was higher than that of S-SGAs. The daily CP dose amount was significantly higher in patients medicated with both generations of antipsychotics than in those given FGAs or S-SGAs. The daily AC dose amount was also significantly higher in patients medicated with both generations of antipsychotics than in those given S-SGAs. CGI-S was significantly higher in patients medicated with FGAs than in those given S-SGAs. Patients medicated with both generations of antipsychotics showed a higher CGI-S compared with those given S-SGAs or NS-SGAs. Regarding satisfaction subscales, effectiveness scores were significantly higher in patients medicated with FGAs than in those medicated with both generations of antipsychotics. Convenience scores were significantly lower in patients medicated with both generations of antipsychotics than in those given FGAs and S-SGAs. No significant difference was found among the groups regarding side effects subscales (Table-1 ).
Correlation between clinical variables and subscales from the questionnaires
To investigate the relationship between the clinical variables and subscales from the questionnaires, Spearmanʼs correlation analysis was performed (Table-3 ). As expected, the daily CP dose showed a significant positive correlation with the daily AC dose and CGI-S. Also as expected, all subscales for satisfaction in TSQM showed a significant positive correlation with all other satisfaction subscales, including effectiveness, side effects (higher side effect score in TSQM indicated a less severe side effect), convenience and global satisfaction. In addition, all satisfaction subscales showed a negative correlation with the subscale for detailed side effects, including sedation, metabolic syndrome and EPS. However, no correlation was seen with global sexual dysfunction or between global satisfaction and sedation, or between convenience and EPS. Excepting sexual dysfunction, all other subscales for detailed side effects showed a significant positive correlation with all other side effects subscales.
Discussion
The aim of the present study was to investigate the commonly accepted theory that the type of antipsychotic used (e. g. FGAs show higher side effects, S-SGAs show a higher risk of metabolic syndrome) reflects satisfaction and dissatisfaction originating from the expected pharmacological features of these drugs in clinical practice. Because this study is based on practical treatments for outpatients with chronic schizophrenia, this was not a fixed cohort study in which medication was controlled. Thus, the type of antipsychotic used, the dose and the concomitant use of an anticholinergic agent were freely adjusted according to the condition of each patient to provide the best pharmacotherapy. This was confirmed by the results that the subscales scores for side effects did not differ among the groups using various antipsychotics (Table-1) and that no correlation between the dose amount of antipsychotics and side effects was seen. However, the dose amounts of antipsychotics showed a positive correlation with the dose amount of anticholinergic agents (Table- 3), and thus, side effects were well controlled in outpatients with schizophrenia, which was expected because they were voluntarily receiving therapy. Important considerations for these rather stable patients are the ʻnext challengesʼ in which patient satisfaction is increased. Regarding satisfaction, the present results showed that the concomitant use of antipsychotics (indicted by ʻBothʼ in Table- 1) had a low rating for effectiveness and convenience compared with the single use of SGAs or FGAs (Table-1 ). Of course, another possibility is that doctors prescribed another type of antipsychotic for concomitant use because a patientʼs symptoms were not sufficiently improved (CGI-S was higher in the ʻBothʼ subgroup, and an increase in the total dose amount of antipsychotics was seen; Table-1) .
The results of the present study are consisted with a previous questionnaire study also using TSQM in chronic patients with schizophrenia in the Arab countries 14) . This study on practical treatments also showed that adherence for patients was affected by effectiveness, convenience, and global satisfaction, but was not by side effects 14) . Sufficient explanations regarding the side effects of each drug were obtained during practical treatments; therefore, dissatisfaction and/or uneasiness concering side effects were not apparent in these studies. For these patients in present and previous studies who were voluntarily receiving therapy, the concomitant use of antipsychotics was not only effective for the remaining symptoms, but also inconvenient. Adherence and compliance for taking medicine are particular important for effectiveness in outpatients with schizophrenia voluntarily receiving therapy 14) 15) . A limitation of the present study was that the number of NS-SGA subjects was too small (n=5); therefore, the influence of side effects on satisfaction could not be detected. Another Japanese study using TSQM showed that satisfaction with regard to side effects was higher with SGA, although they did not differentiate the SGA into S-SGA and NS-SGA 16) . The influence of side effects on satisfaction may be clarified in future studies using a larger number of subjects in the S-SGA and NS-SGA groups.
To identify the needs of patients with chronic schizophrenia, questionnaires are one of the best methods for patients to report their distress without involving difficult verbal communication 7) ; in particular self-administered questionnaires are better for revealing hidden distress 8) . The results of the present questionnaire study showed that patients with chronic schizophrenia are wishing to get further convenience in taking medicine and effectiveness to remaining symptoms in their pharmacotherapies. A questionnaire study investigating pharmacological adherence in another major psychiatric disorder, bipolar disorder, also revealed that the important factors for adherences were collaboration, empathy and accessibility for their doctors; however discussing the risk of medication and benefits of drug treatment was not associated with medication adherence 17) . Therefore, an emotional connection between the clinician and psychiatric patients may have an important association with pharmacological adherence. Questionnaires could be particularly useful in establishing communication with patients with schizophrenia who have difficulties with verbal communication.
Conclusion
Side effects are sometimes seen as the most troublesome factor for patients with schizophrenia 18) , but for outpatients voluntarily receiving pharmacotherapy, side effects were not the main dissatisfaction factor because these were controlled to a certain extent in practical treatment. For these patients, convenience and effectiveness were the most important factors for satisfaction, and psychiatrists should be aware of these and prescribe the most effective pharmacological treatment for any remaining symptoms.
